Cyclo Therapeutics develops cyclodextrin-based products for treating diseases and selling them to the pharmaceuticals, nutritionals, and other industries. Their leading drug candidate is Trappsol Cyclo, which is in Phase III clinical trials for treating Niemann-Pick Type C disease, with another goal being Alzheimer's disease. The company changed its name from CTD Holdings, Inc. to Cyclo Therapeutics, Inc., and was founded in 1990, with its headquarters located in Florida.